Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment

Trevi Therapeutics, Inc.

2024-Q3 EPS reported -$0.36

Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.
Cash, cash equivalents and marketable securities of $65.5M at quarter end; expected runway into H2 2026.
Completed enrollment in Phase 2a RIVER trial for refractory chronic cough; topline results expected Q1 2025.
Enrolled 50% of planned 160 patients in Phase 2b CORAL trial for chronic cough in IPF; SSRE outcome expected Dec 2024; topline H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.